AIMASNCT07083726
Smart Steps to Growth: Unleashing AI for Assessing Motor Skills in School Children
An observational study of AIMAS and Developmental Coordination Disorder, run by Chang Gung Memorial Hospital at 1 site in Taiwan.
Trial summary
The purpose of this study is to develop an AI-based automated motor function assessment system (AIMAS) to improve early identification of developmental coordination disorder (DCD) in school-age children. Read more about this study
- Who is it for?
- Ages 6 to 12 years
- Conditions the study is for
- AIMAS, Developmental Coordination Disorder
- How many people
- 250 participants
- Where
- 1 siteTaiwan
- Study dates
- 1 Aug 2025to 31 Jul 2028
- How long will I take part?
- 3 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 6 to 12 years
- All sexes
- No healthy volunteers
- Child
Study population: The study will recruit 250 school-age children, aged 6 to 12, including 170 typically developing children and 80 children with DCD.
Who may be able to join
- Children aged 6 to 12 years.
- For DCD group: formal diagnosis of Developmental Coordination Disorder (DCD).
- For typically developing group: no disabilities or developmental delays.
Who cannot join
- Acute illnesses (e.g., pneumonia, upper gastrointestinal hemorrhage).
- Significant developmental delays or disabilities.
- Genetic diseases or disorders.
- Neurological disorders or injuries.
Trial locations and contacts
1 site in 1 country.
About this study
The purpose of this study is to develop an AI-based automated motor function assessment system (AIMAS) to improve early identification of developmental coordination disorder (DCD) in school-age children. The main hypothesis for this study is: Integrating AI into motor skill assessments will enhance the reliability, validity, efficiency, and accuracy of evaluating motor performance in children aged 6 to 12.
- Conditions
- AIMAS, Developmental Coordination Disorder
- Keywords
- Schoolchildren, Assessment, Artificial Intelligence, Motor, Developmental coordination disorder
- Medical subject headings
- Motor Skills Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Typically Developing Children | School-age children aged 6 to 12 years who do not have a diagnosis of developmental coordination disorder (DCD). | |
| Developmental Coordination Disorder children | School-age children aged 6 to 12 years who have a confirmed diagnosis of DCD. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Motor Function Assessment Score
AI-based Motor Function Test (Higher scores indicate better motor performance and lower risk of Developmental Coordination Disorder (DCD).)
Measured: Baseline
DCD Risk Classification
AIMAS System Classification (System's ability to identify children at risk of DCD, compared to clinical diagnosis.)
Measured: Baseline
Secondary outcomes (1)
The Bruininks-Oseretsky Test of Motor Proficiency, Second Edition (BOT-2)
Measured: baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Jul 2025
- Study start1 Aug 2025
- Primary completion31 Jul 2028 (estimated)
- Study completion31 Jul 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for AIMASStudies of the same condition, open and under way.
- More trials run by Chang Gung Memorial HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 250 participants (estimated)
- Target duration
- 3 Years
Sponsor and investigators
- Lead sponsor
- Chang Gung Memorial Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Chia-Ling Chen, Study director, Chang Gung Memorial Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07083726
- Sponsor's protocol ID
- 202401852B0
- Status last verified
- Jul 2025
- First submitted
- 16 Jul 2025
- Last updated
- 5 Sep 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 5 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Smart Steps to Growth: Unleashing AI for Assessing Motor Skills in School Children
- ClinicalTrials.gov ID
- NCT07083726
- Acronym / sponsor ID
- 202401852B0
- Conditions
- AIMAS, Developmental Coordination Disorder
- Keywords
- Schoolchildren, Assessment, Artificial Intelligence, Motor, Developmental coordination disorder
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 250 participants (estimated)
- Lead sponsor
- Chang Gung Memorial HospitalUniversity, hospital or other
- Study start
- 1 Aug 2025 (actual)
- Primary completion
- 31 Jul 2028 (estimated)
- Study completion
- 31 Jul 2028 (estimated)
- First posted
- 24 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to develop an AI-based automated motor function assessment system (AIMAS) to improve early identification of developmental coordination disorder (DCD) in school-age children. The main hypothesis for this study is: Integrating AI into motor skill assessments will enhance the reliability, validity, efficiency, and accuracy of evaluating motor performance in children aged 6 to 12.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 3 Years
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Typically Developing Children | – | –School-age children aged 6 to 12 years who do not have a diagnosis of developmental coordination disorder (DCD). |
| Developmental Coordination Disorder children | – | –School-age children aged 6 to 12 years who have a confirmed diagnosis of DCD. |
Who may qualify
- Ages
- 6 to 12 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
- Study population
- The study will recruit 250 school-age children, aged 6 to 12, including 170 typically developing children and 80 children with DCD.
Key inclusion criteria (3 listed)
- Children aged 6 to 12 years.
- For DCD group: formal diagnosis of Developmental Coordination Disorder (DCD).
- For typically developing group: no disabilities or developmental delays.
Key exclusion criteria (4 listed)
- Acute illnesses (e.g., pneumonia, upper gastrointestinal hemorrhage).
- Significant developmental delays or disabilities.
- Genetic diseases or disorders.
- Neurological disorders or injuries.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Motor Function Assessment Score
Time frame: Baseline
AI-based Motor Function Test (Higher scores indicate better motor performance and lower risk of Developmental Coordination Disorder (DCD).)
DCD Risk Classification
Time frame: Baseline
AIMAS System Classification (System's ability to identify children at risk of DCD, compared to clinical diagnosis.)
1 secondary outcome
The Bruininks-Oseretsky Test of Motor Proficiency, Second Edition (BOT-2)
Time frame: baseline
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Sep 2025.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Chia-Ling Chen study director
Chang Gung Memorial Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of AIMAS and Developmental Coordination Disorder, run by Chang Gung Memorial Hospital at 1 site in Taiwan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 5 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Motor Function Assessment Score (time frame: Baseline). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Sep 2025.